JP2004508327A - 下剤組成物 - Google Patents

下剤組成物 Download PDF

Info

Publication number
JP2004508327A
JP2004508327A JP2002524492A JP2002524492A JP2004508327A JP 2004508327 A JP2004508327 A JP 2004508327A JP 2002524492 A JP2002524492 A JP 2002524492A JP 2002524492 A JP2002524492 A JP 2002524492A JP 2004508327 A JP2004508327 A JP 2004508327A
Authority
JP
Japan
Prior art keywords
triglyceride
formula
fatty acid
bicyclic
carbon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002524492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004508327A5 (OSRAM
Inventor
上野　隆司
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24630250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2004508327(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Publication of JP2004508327A publication Critical patent/JP2004508327A/ja
Publication of JP2004508327A5 publication Critical patent/JP2004508327A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
JP2002524492A 2000-09-05 2001-09-04 下剤組成物 Pending JP2004508327A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/655,760 US6414016B1 (en) 2000-09-05 2000-09-05 Anti-constipation composition
PCT/JP2001/007628 WO2002020007A1 (en) 2000-09-05 2001-09-04 Cathartic composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009050902A Division JP4684334B2 (ja) 2000-09-05 2009-03-04 下剤組成物

Publications (2)

Publication Number Publication Date
JP2004508327A true JP2004508327A (ja) 2004-03-18
JP2004508327A5 JP2004508327A5 (OSRAM) 2005-12-22

Family

ID=24630250

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002524492A Pending JP2004508327A (ja) 2000-09-05 2001-09-04 下剤組成物
JP2009050902A Expired - Fee Related JP4684334B2 (ja) 2000-09-05 2009-03-04 下剤組成物
JP2009213058A Pending JP2009286806A (ja) 2000-09-05 2009-09-15 下剤組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009050902A Expired - Fee Related JP4684334B2 (ja) 2000-09-05 2009-03-04 下剤組成物
JP2009213058A Pending JP2009286806A (ja) 2000-09-05 2009-09-15 下剤組成物

Country Status (25)

Country Link
US (7) US6414016B1 (OSRAM)
EP (2) EP1315485B1 (OSRAM)
JP (3) JP2004508327A (OSRAM)
KR (2) KR100901102B1 (OSRAM)
CN (1) CN100335049C (OSRAM)
AR (2) AR030609A1 (OSRAM)
AT (1) ATE476975T1 (OSRAM)
AU (2) AU8261501A (OSRAM)
BR (1) BRPI0114042B8 (OSRAM)
CA (1) CA2419741C (OSRAM)
CZ (1) CZ304740B6 (OSRAM)
DE (2) DE60142810D1 (OSRAM)
DK (2) DK1315485T3 (OSRAM)
ES (2) ES2296786T3 (OSRAM)
HU (1) HU229319B1 (OSRAM)
IL (2) IL154534A0 (OSRAM)
MX (1) MXPA03001959A (OSRAM)
NL (1) NL300757I1 (OSRAM)
NO (1) NO332701B1 (OSRAM)
NZ (1) NZ524401A (OSRAM)
PT (2) PT1857105E (OSRAM)
RU (1) RU2694361C3 (OSRAM)
TW (1) TWI305147B (OSRAM)
WO (1) WO2002020007A1 (OSRAM)
ZA (1) ZA200301673B (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008511541A (ja) * 2004-09-02 2008-04-17 スキャンポ・アーゲー 胃腸障害処置用プロスタグランジン誘導体
JP2011516430A (ja) * 2008-04-01 2011-05-26 上海天偉生物制薬有限公司 ルビプロストン結晶、その製造方法および用途
JP2011256201A (ja) * 2006-02-07 2011-12-22 R Tec Ueno:Kk プロスタグランジン誘導体の製造法

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100830061B1 (ko) 1999-10-15 2008-05-16 수캄포 아게 이환식 화합물 조성물 및 이의 안정화 방법
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
WO2004037268A1 (en) * 2002-10-23 2004-05-06 Sucampo Ag Prostaglandin compounds for the treatment of obesity
MXPA05006981A (es) * 2002-12-27 2005-12-14 Sucampo Ag Derivados de prostaglandinas para el tratamiento de la molestia abdominal.
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
CN101048163A (zh) * 2004-09-02 2007-10-03 苏坎波公司 用于治疗胃肠道疾病的前列腺素衍生物
US8202909B2 (en) 2005-01-27 2012-06-19 Sucampo Ag Method for treating central nervous system disorders
EP1853271B1 (en) * 2005-03-04 2010-12-01 Sucampo AG Method and composition for treating peripheral vascular diseases
CN101171010B (zh) * 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
JP5711442B2 (ja) * 2005-04-12 2015-04-30 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 胃腸障害の処置のためのプロスタグランジン化合物およびプロトンポンプ阻害剤の併用
CN101466407B (zh) * 2006-01-24 2013-05-15 株式会社·R-技术上野 包含双环化合物的药物组合物和使所述双环化合物稳定的方法
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
ES2633726T3 (es) * 2008-10-31 2017-09-25 Lipid Pharmaceuticals Ehf. Ácidos grasos para utilizar como medicamento
EP3351248B1 (en) 2008-12-31 2021-06-09 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2750487A1 (en) 2009-01-22 2010-07-29 Apotex Pharmachem Inc. Methods of making lubiprostone and intermediates thereof
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
TW201118084A (en) * 2009-09-18 2011-06-01 Adolor Corp The use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders
WO2011054087A1 (en) * 2009-11-03 2011-05-12 Bernard Charles Sherman Stable pharmaceutical formulations comprising lubiprostone
US20120309990A1 (en) * 2009-12-18 2012-12-06 Apotex Pharmachem Inc. Processes for the Purification of Lubiprostone
CA2788334A1 (en) 2010-01-28 2011-08-04 Apotex Pharmachem Inc. Polymorphic forms of lubiprostone
CA2880338A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
KR102287207B1 (ko) 2013-04-12 2021-08-09 알데릭스, 인코포레이티드 Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법
EP3277274B1 (en) 2015-04-01 2024-06-12 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
WO2016203317A1 (en) * 2015-06-19 2016-12-22 Sucampo Ag Pharmaceutical compositions comprising fatty acid derivative
WO2018065826A1 (en) 2016-10-06 2018-04-12 Sucampo Ag Multilayer beads for pharmaceutical use
JP2020505333A (ja) 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Ｎｈｅ媒介性アンチポートの阻害薬
CN110267944B (zh) 2017-01-09 2024-03-08 阿德利克斯股份有限公司 可用于治疗胃肠道病症的化合物
JP6750733B2 (ja) * 2017-04-20 2020-09-02 株式会社島津製作所 分光光度計
US10422729B1 (en) 2019-03-08 2019-09-24 Biodesix, Inc. Blood sample separation devices and methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5720305B2 (OSRAM) 1973-02-28 1982-04-27
US4034003A (en) 1974-04-11 1977-07-05 Ono Pharmaceutical Co., Ltd. 15-Cycloalkyl-prostaglandins
JPS5350141A (en) 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
JPS5391110A (en) 1977-01-20 1978-08-10 Yamanouchi Pharmaceut Co Ltd Novel drug composition for rectal infusion
JPS6022708B2 (ja) 1977-07-14 1985-06-03 小野薬品工業株式会社 プロスタグランジン類似化合物
US4308595A (en) * 1979-12-19 1981-12-29 International Business Machines Corporation Array driver
US4670569A (en) 1981-04-02 1987-06-02 G. D. Searle & Co. 5-fluoro-PGI2 compounds
US4687864A (en) 1983-12-23 1987-08-18 G. D. Searle & Co. 5-fluoro-3-oxa-prostacyclin compounds
US4579958A (en) 1983-12-23 1986-04-01 G. D. Searle & Co. 5-fluoro-3-oxa-6,7-didehydro-PGI1 compounds
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
ATE78465T1 (de) * 1987-10-02 1992-08-15 Ueno Seiyaku Oyo Kenkyujo Kk Kathartica.
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
JP2515442B2 (ja) * 1990-05-01 1996-07-10 株式会社上野製薬応用研究所 膵臓疾患処置剤
JP2938579B2 (ja) 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US5958876A (en) * 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
AUPO665397A0 (en) * 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
WO1999045934A1 (fr) * 1998-03-11 1999-09-16 Grelan Pharmaceutical Co., Ltd. Preparations entero-solubles effervescentes
US6471085B1 (en) 1999-10-04 2002-10-29 Anthony J. Gallo Temperature cup
KR100830061B1 (ko) * 1999-10-15 2008-05-16 수캄포 아게 이환식 화합물 조성물 및 이의 안정화 방법
DE50107923D1 (de) * 2000-07-14 2005-12-08 Henkel Kgaa Kompartiment-hohlkörper enthaltend wasch-, reinigungs- oder spülmittelportion
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008511541A (ja) * 2004-09-02 2008-04-17 スキャンポ・アーゲー 胃腸障害処置用プロスタグランジン誘導体
JP2013049688A (ja) * 2004-09-02 2013-03-14 Sucampo Ag 胃腸障害処置用プロスタグランジン誘導体
JP2015166377A (ja) * 2004-09-02 2015-09-24 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 胃腸障害処置用プロスタグランジン誘導体
JP2011256201A (ja) * 2006-02-07 2011-12-22 R Tec Ueno:Kk プロスタグランジン誘導体の製造法
JP2011516430A (ja) * 2008-04-01 2011-05-26 上海天偉生物制薬有限公司 ルビプロストン結晶、その製造方法および用途

Also Published As

Publication number Publication date
EP1857105B1 (en) 2010-08-11
PT1857105E (pt) 2010-10-08
US8748454B2 (en) 2014-06-10
US20140235665A1 (en) 2014-08-21
US20030040528A1 (en) 2003-02-27
US20030216465A1 (en) 2003-11-20
NO20030996L (no) 2003-05-02
BRPI0114042B8 (pt) 2021-05-25
CN1655776A (zh) 2005-08-17
NO332701B1 (no) 2012-12-10
EP1315485B1 (en) 2007-11-21
AR030609A1 (es) 2003-08-27
US20120022152A1 (en) 2012-01-26
BRPI0114042B1 (pt) 2016-11-08
ES2347697T3 (es) 2010-11-03
US20120237598A1 (en) 2012-09-20
MXPA03001959A (es) 2003-06-24
DK1315485T3 (da) 2008-03-03
DE60131547D1 (de) 2008-01-03
EP1315485A1 (en) 2003-06-04
AU8261501A (en) 2002-03-22
AU2001282615B2 (en) 2006-06-22
KR20030029919A (ko) 2003-04-16
HUP0302422A2 (hu) 2003-10-28
DE60142810D1 (de) 2010-09-23
EP1857105A2 (en) 2007-11-21
JP4684334B2 (ja) 2011-05-18
ES2296786T3 (es) 2008-05-01
CN100335049C (zh) 2007-09-05
CA2419741C (en) 2010-11-30
US6414016B1 (en) 2002-07-02
TWI305147B (en) 2009-01-11
RU2694361C9 (ru) 2019-12-25
KR100918223B1 (ko) 2009-09-21
DK1857105T3 (da) 2010-09-20
RU2694361C3 (ru) 2020-07-20
RU2694361C2 (ru) 2019-07-12
IL154534A (en) 2010-04-29
CZ304740B6 (cs) 2014-09-17
NO20030996D0 (no) 2003-03-04
ZA200301673B (en) 2003-11-26
US8071613B2 (en) 2011-12-06
HU229319B1 (en) 2013-10-28
PT1315485E (pt) 2008-01-23
JP2009114217A (ja) 2009-05-28
KR20080091278A (ko) 2008-10-09
EP1857105A3 (en) 2008-03-05
NL300757I2 (OSRAM) 2015-12-29
HUP0302422A3 (en) 2005-02-28
AR100291A2 (es) 2016-09-28
JP2009286806A (ja) 2009-12-10
WO2002020007A1 (en) 2002-03-14
NZ524401A (en) 2004-08-27
CA2419741A1 (en) 2002-03-14
US20050222195A1 (en) 2005-10-06
US6610732B2 (en) 2003-08-26
NL300757I1 (OSRAM) 2015-12-29
US8114890B1 (en) 2012-02-14
KR100901102B1 (ko) 2009-06-08
ATE476975T1 (de) 2010-08-15
DE60131547T2 (de) 2008-10-23
BR0114042A (pt) 2003-07-22
IL154534A0 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
JP4684334B2 (ja) 下剤組成物
AU2001282615A1 (en) Cathartic composition
WO2009005172A1 (en) Pharmaceutical combination of nsaid and prostaglandin compound
WO2004060377A1 (en) Derivatives of prostaglandins for treating abdominal discomfort
US7459583B2 (en) Method for providing a cathartic effect
JPH0739344B2 (ja) 眼圧降下剤
JPH07103096B2 (ja) プロスタグランジンｄ類およびそれを含む鎮静・睡眠剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090304

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20090317

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20090327